6978 — Immunotech Biopharm Cashflow Statement
0.000.00%
Last trade - 00:00- HK$1.87bn
- HK$2.34bn
Annual cashflow statement for Immunotech Biopharm, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -439 | -355 | -321 | -335 | -186 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 191 | 59.9 | 51 | 106 | -22 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -29.3 | 19.1 | 45.1 | 12.3 | 21.8 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -264 | -255 | -181 | -164 | -126 |
| Capital Expenditures | -75.7 | -181 | -96.6 | -22.5 | -28.1 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -128 | -147 | 120 | -94.1 | 169 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -204 | -328 | 23.4 | -117 | 141 |
| Financing Cash Flow Items | -77.9 | -3.68 | -19.6 | -8.52 | -7.49 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1,055 | -11 | -36.1 | 274 | -20.6 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 563 | -594 | -193 | -6.29 | -5.2 |